Live Updates Live Coverage Has Ended This Dial Goes to 5 4:18 pm The Vanguard S&P 500 ETF closed Friday at 546.26, up 0.6% ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

U.S. Secretary of State Marco Rubio said on Thursday that all NATO members will have agreed on a goal of spending the ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

Commonwealth Bank of Australia (CBA) reported a 6% rise in third-quarter cash earnings on Wednesday, helped by growth in ...

Yahoo Finance has all the latest market moving Merger & IPO news and analysis to help you stay up to date and make informed ...

European stock markets hovered around the flatline on Monday, as investors gauged potential trade negotiations between the ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy.

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth quarter ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, ...